Guardant Health prelim Q4 revenue rises 39%, beats expectations

Overview

• Precision oncology firm's preliminary Q4 revenue rises 39%, beating analyst expectations

• Company reports 38% increase in oncology test volumes for Q4 2025

Outlook

• Guardant Health expects continued growth in oncology with new product launches

• Company anticipates Shield's expanded capabilities to enhance clinical value in 2026

• Guardant Health did not provide specific financial guidance for future periods

Result Drivers

• ONCOLOGY TEST VOLUME - Co reported a 38% increase in oncology test volumes, driven by innovations from the Smart Platform and commercial execution

• SHIELD SCREENING GROWTH - Shield screening tests jumped from 6,400 to 38,000, bolstered by multi-cancer detection capabilities

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Guardant Health Inc is $120.00, about 8.9% above its January 9 closing price of $110.17

Press Release: ID:nBw2V8VVda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.